☆ 4.4 Article

Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy

THORACIC CANCER (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz-Ares et al.

Summary: The combination of first-line nivolumab plus ipilimumab with a limited course of chemotherapy showed a significant improvement in overall survival for patients with advanced non-small-cell lung cancer, supporting it as a new treatment option for this patient population.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers

Riccardo Lobefaro et al.

Summary: The study found that for patients with Non-Small Cell Lung Cancer, the worse the Performance Status (PS) is, the lower the efficacy of immunotherapy, with patients with PS2 showing poorer outcomes in terms of disease control rate, progression free survival, and overall survival. Additionally, LDH levels and corticosteroid exposure were also associated with patient outcomes.

LUNG CANCER (2021)

Add to Collection

Article Oncology

The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer

G. L. Banna et al.

Summary: This study focused on stratifying the prognosis of patients with PD-L1 >= 50% aNSCLC. It found that NLR < 4 was a significant prognostic factor and developed a risk model named lung immuno-oncology prognostic score (LIPS)-3 to accurately categorize patients into different risk levels for prognosis.

ESMO OPEN (2021)

Add to Collection

Article Oncology

SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2

Michael Mark et al.

Summary: First-line durvalumab in patients with metastatic NSCLC with PD-L1 expression >= 25% and an ECOG PS2 status resulted in unexpectedly high number of fatal early events due to rapid tumor progression. It is recommended to avoid treatment with 1L durvalumab for patients highly symptomatic from the tumor, particularly those with respiratory symptoms. The study is continuing with exclusion of these patients.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Oncology

CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations

Enriqueta Felip et al.

EUROPEAN JOURNAL OF CANCER (2020)

Add to Collection

Article Oncology

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

Alessio Cortellini et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)

Add to Collection

Article Oncology

First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status

Francesco Facchinetti et al.

EUROPEAN JOURNAL OF CANCER (2020)

Add to Collection

Article Critical Care Medicine

Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial

Gary Middleton et al.

LANCET RESPIRATORY MEDICINE (2020)

Add to Collection

Article Oncology

Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab

Alex Friedlaender et al.

ACTA ONCOLOGICA (2020)

Add to Collection

Article Oncology

Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab

Giuseppe Luigi Banna et al.

TRANSLATIONAL LUNG CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)

David R. Spigel et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

Add to Collection

Review Oncology

Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis

Alfredo Addeo et al.

FRONTIERS IN ONCOLOGY (2019)

Add to Collection

Meeting Abstract Oncology

CheckMate 817: First-Line Nivolumab plus Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC

F. Barlesi et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

Add to Collection

Review Oncology

Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era

Alex Friedlaender et al.

CURRENT ONCOLOGY REPORTS (2019)

Add to Collection

Article Oncology

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

D. Planchard et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

© Peeref 2019-2024. All rights reserved.